

JOURNAL SELECTION

THE SYSTEMIC TREATMENTS FOR DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) BEYOND CORTICOSTEROIDS

SAMPLE WORK

copyrights @ 2026 pubrica. No part of this document may be published without permission of the author

Journal Selection Report

Job code	xxxxxxx
Manuscript title	The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids
Date	xxxxx
Author preferences	**Keywords:** Corticosteroid; Cyclosporine; Drug reaction with eosinophilia and systemic symptoms; Drug-induced hypersensitivity syndrome; IL-5/IL-5R inhibitors.
Comments on Adherence to Author Preferences	All recommended journals have regularly published articles on topics related to the authors' Area of Research / Idea

Journal Recommendations

Journal name	Comments
Journal of the American Academy of Dermatology *Publisher: Elsevier*	**The Reason for the recommendation:** 1. The *Journal of the American Academy of Dermatology* is a leading peer-reviewed international journal that publishes high-quality clinical and translational research in dermatology. The journal features original investigations, systematic reviews, and evidence-based updates on severe cutaneous adverse reactions, including drug reactions with eosinophilia and systemic symptoms (DRESS). It places strong emphasis on therapeutic innovations, clinical management strategies, and patient outcomes in dermatologic emergencies. Given its focus on treatment advances and practical clinical guidance, JAAD provides a suitable platform for an article exploring systemic treatment options beyond corticosteroids for DRESS, particularly from a dermatology-driven clinical perspective. 2. The journal published several articles on topics like authors' Area of Research / Idea, e.g., • Husain, Z., Reddy, B. Y., & Schwartz, R. A. (2013). DRESS syndrome: Part I. Clinical perspectives. *Journal of the American Academy of Dermatology*, 68(5), 693.e1–708. https://doi.org/10.1016/j.jaad.2013.01.033 • Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013). Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. *Journal of the American Academy of Dermatology*, 69(2), 187.e1–204. https://doi.org/10.1016/j.jaad.2013.05.002

SAMPLE WORK

Copyright © 2026 pubrica. No part of this document may be published without permission of the author

The Journal of Allergy and Clinical Immunology *Publisher: Elsevier.*	**The Reason for the recommendation:** 1. *The Journal of Allergy and Clinical Immunology* is a high-impact peer-reviewed journal dedicated to research in allergy, immunology, and immune-mediated disorders. The journal publishes original clinical studies, translational research, and comprehensive reviews addressing drug hypersensitivity reactions and immune dysregulation. As DRESS is a severe T-cell–mediated hypersensitivity syndrome characterized by eosinophilia and systemic immune activation, JACI represents an appropriate venue for manuscripts examining immunopathogenesis and targeted systemic therapies. An article discussing steroid-sparing agents, biologics, and cytokine-directed treatment approaches would align well with the journal's emphasis on mechanism-driven therapeutic advances. 2. The journal published several articles on topics like authors' Area of Research / Idea, e.g., • Kaplan A. P. (1984). Drug-induced skin disease. *The Journal of allergy and clinical immunology*, 74(4 Pt 2), 573–579. https://doi.org/10.1016/0091-6749(84)90109-x • Weare-Regales, N., Carr, T., Holguin, F., Tibbitt, C. A., & Lockey, R. F. (2024). Obesity and hormonal influences on asthma: Mechanisms, management challenges, and emerging therapeutic strategies. *The Journal of Allergy and Clinical Immunology*, 154(6), 1355–1368. https://doi.org/10.1016/j.jaci.2024.09.018
Clinical Pharmacology & Therapeutics *Publisher: Wiley-Blackwell*	**The Reason for the recommendation:** 1. *Clinical Pharmacology & Therapeutics* is an internationally recognized peer-reviewed journal that focuses on drug development, pharmacodynamics, pharmacogenomics, and adverse drug reactions. The journal welcomes research and reviews addressing precision medicine approaches, drug safety, and therapeutic optimization. Considering that DRESS is a severe drug-induced hypersensitivity reaction requiring careful pharmacologic management, this journal is particularly suitable for manuscripts emphasizing systemic treatment strategies beyond corticosteroids, pharmacologic mechanisms of action, safety considerations, and risk–benefit evaluation of emerging therapies. A therapeutics-focused review highlighting evidence-based management and individualized treatment strategies would align strongly with its scope. 2. The journal published several articles on topics like authors 'Area of Research / Idea, e.g., • Mahar, K. M., Yang, S., Johnson, B., Visser, S. A. G., van den Berg, P., van Noort, M., & Post, T. M. (2026). Model-informed drug development for daprodustat supports the design of individualized dosing regimens in chronic kidney disease patients with anemia. *Clinical Pharmacology and Therapeutics*, 119(2), 322–335. https://doi.org/10.1002/cpt.70094

SAMPLE WORK

Copyright © 2026 pubrica. No part of this document may be published without permission of the author

	• Dong, W., Zhang, H., Mu, S., Shi, S., Zhang, J., & Xu, K. (2026). Advances in incretin-based therapies for MAFLD: Mechanisms and clinical evidence. *Clinical Pharmacology and Therapeutics*, 119(2), 336–349. https://doi.org/10.1002/cpt.70131

Journal Comparator

Key Parameters		Journal of the American Academy of Dermatology	The Journal of Allergy and Clinical Immunology	Clinical Pharmacology & Therapeutics
Publisher		Elsevier	Elsevier	Wiley-Blackwell
Similar research published		Yes	Yes	Yes
Indexing database		MEDLINE/PubMed, Scopus, SCIE SJR, SNIP .	MEDLINE/PubMed, Abridged Index Medicus, Core clinical journals (AIM)	MEDLINE/PubMed/Index Medicus, Scopus, Science Citation Index (Web of Science), Chemical Abstracts Service.
Impact factor		11.8	11.2	6.3
Review duration		4–8 weeks for the peer-review process	First review round typically takes about 0.9 to 1 month	Approximately 1.5 months (6 weeks) for the first review round.
Publication type		Peer-reviewed medical journal, Official scientific publication of the American Academy of Dermatology (AAD).	Peer-reviewed medical journal, Official journal of the American Academy of Allergy, Asthma, and Immunology (AAAAI).	Peer-reviewed scientific journal, Official journal of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Rejection rate		Approximately 50%	**82%**	Approximately **15%**
Acceptance rate		29% to 43%	Approximately **20%**.	Approximately **15%** for original research.
Article processing charges		**$4,500 USD**	**$5,200 USD**	**$4,630 USD**
Limit	**Word count**	Max 2,500 words	Max 3,500 words	Max 4,000 words
	Figure/Tables	Max 5 total	Max 8 total	Max 7
	References	No limit	Not specified	Max 50

SAMPLE WORK

Copyright © 2026 pubrica. No part of this document may be published without permission of the author

Supporting Information - Rationale for Inclusion and Scope

Journal of the American Academy of Dermatology	
Rationale for inclusion	A peer-reviewed, internationally recognized dermatology journal that publishes high-quality clinical and translational research on severe cutaneous adverse reactions, including drug-induced hypersensitivity syndromes such as DRESS. The journal provides a strong platform for advancing therapeutic strategies, clinical management approaches, and outcome-based dermatologic research.
Scope	Covers all aspects of dermatologic diseases, including inflammatory and immune-mediated disorders, drug reactions, dermatologic emergencies, systemic immunomodulatory therapies, biologics, clinical trials, treatment guidelines, and evidence-based advances in dermatologic care.

The Journal of Allergy and Clinical Immunology	
Rationale for inclusion	A high-impact, peer-reviewed journal dedicated to allergy, immunology, and immune-mediated diseases. It publishes cutting-edge research on drug hypersensitivity reactions, immune dysregulation, and targeted biologic therapies, making it a suitable venue for manuscripts examining the immunopathogenesis and systemic treatment strategies of DRESS beyond corticosteroids.
Scope	Encompasses clinical and translational research in allergy and immunology, including T-cell–mediated hypersensitivity reactions, cytokine signaling pathways, immune biomarkers, biologic therapies, pharmacologic interventions, and mechanism-driven therapeutic advancements.

Clinical Pharmacology & Therapeutics	
Rationale for inclusion	An internationally recognized peer-reviewed journal focusing on drug safety, pharmacogenomics, and therapeutic innovation. It provides a platform for research addressing adverse drug reactions and precision medicine approaches, aligning well with a manuscript exploring systemic pharmacologic management and steroid-sparing treatment strategies in DRESS.
Scope	Covers drug development, pharmacodynamics, pharmacokinetics, pharmacogenetics, adverse drug reactions, therapeutic optimization, personalized medicine, safety evaluation, and translational clinical pharmacology research.

SAMPLE WORK

Copyright © 2026 pubrica. No part of this document may be published without permission of the author

Appendix: Frequently Asked Questions

Q1: Why are these journals suitable for research on systemic treatment strategies in DRESS?

A: These journals publish high-quality research on severe drug reactions, immune-mediated disorders, systemic therapies, and precision pharmacology, directly aligning with DRESS management and steroid-sparing treatment strategies.

Q2: How does this manuscript align with the scope and readership of these journals?

A: The manuscript targets dermatologists, immunologists, and pharmacologists by addressing immune mechanisms, systemic immunomodulation, and evidence-based therapeutic optimization in severe drug hypersensitivity reactions.

Q3: How quickly are submissions typically reviewed?

A: Initial editorial decisions are typically provided within two to five months, depending on manuscript type, peer-review complexity, and journal-specific editorial workflows.

Q4: How widely are these journals indexed?

A: All three journals are indexed in major international databases including PubMed/MEDLINE, Scopus, and Web of Science, ensuring strong global visibility and citation potential.

Q5: How does publishing here impact academic reach?

A: Publishing enhances international visibility, strengthens academic credibility, increases citation opportunities, and supports dissemination of evidence-based systemic treatment strategies for severe drug hypersensitivity syndromes.

SAMPLE WORK

Copyright © 2026 pubrica. No part of this document may be published without permission of the author